Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | CTSC | P53634 | 4/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.40 |
| ▸ | MAN2A1 | Q16706 | 1/20 | 0.40 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16015166 | 1.00 | CYP3A4 (0.55) | CYP3A4CYP2D6CYP1A2CYP2C19CTSC | |
| SCHEMBL16376134 | 1.00 | CYP3A4 (0.55) | CYP3A4CYP2D6CYP1A2CYP2C19CTSC | |
| SCHEMBL16139975 | 1.00 | CYP3A4 (0.55) | CYP3A4CYP2D6CYP1A2CYP2C19CTSC | |
| SCHEMBL16015165 | 1.00 | CYP3A4 (0.55) | CYP3A4CYP2D6CYP1A2CYP2C19CTSC | |
| SCHEMBL20193704 | 0.93 | CYP3A4 (0.52) | CYP3A4CYP2D6CYP1A2CYP2C19CTSC | |
| SCHEMBL13974186 | 0.85 | CYP3A4 (0.57) | CYP3A4CYP2D6CYP1A2CYP2C19CTSC | |
| SCHEMBL24056571 | 0.83 | LMNA (0.60) | CYP3A4CYP2D6CYP1A2CYP2C19CTSC | |
| SCHEMBL7305357 | 0.83 | LMNA (0.60) | CYP3A4CYP2D6CYP1A2CYP2C19CTSC | |
| SCHEMBL24057819 | 0.83 | LMNA (0.60) | CYP3A4CYP2D6CYP1A2CYP2C19CTSC | |
| SCHEMBL7313727 | 0.81 | RECQL (0.62) | CYP3A4CYP2D6CYP1A2CYP2C19CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398529-A1 | ASYMMETRIC TRANSFER HYDROGENATION OF 2-ARYL SUBSTITUTED BICYCLIC PYRIDINE KETONES IN PRESENCE OF A CHIRAL RUTHENIUM CATALYST | BAYER AKTIENGESELLSCHAFT (DE) | 2023-12-14 | — | — | US | disclosed |
| EP-3819295-A1 | STEREOSELECTIVE SYNTHESIS OF ENANTIOMERICALLY-ENRICHED PANTOLACTONE | DSM IP Assets B.V. (NL) | 2021-05-12 | — | — | EP | disclosed |
| WO-2019228874-A1 | STEREOSELECTIVE SYNTHESIS OF ENANTIOMERICALLY-ENRICHED PANTOLACTONE | DSM IP ASSETS B.V. (NL) | 2019-12-05 | — | — | WO | disclosed |
| US-9981935-B2 | Formation of chiral 4-chromanones using chiral pyrrolidines in the presence of acids | DSM IP ASSETS B.V. (NL) | 2018-05-29 | — | — | US | disclosed |
| US-9981935-B2 | Formation of chiral 4-chromanones using chiral pyrrolidines in the presence of acids | DSM IP ASSETS B.V. (NL) | 2018-05-29 | — | — | US | disclosed |
| US-9815809-B2 | Formation of chiral 4-chromanones using chiral pyrrolidines in the presence of phenols or thiophenols | DSM IP ASSETS B.V. (NL) | 2017-11-14 | — | — | US | disclosed |
| US-9815809-B2 | Formation of chiral 4-chromanones using chiral pyrrolidines in the presence of phenols or thiophenols | DSM IP ASSETS B.V. (NL) | 2017-11-14 | — | — | US | disclosed |
| US-9809565-B2 | Formation of chiral 4-chromanones using chiral pyrrolidines in the presence of ureas or thioureas | DSM IP ASSETS B.V. (NL) | 2017-11-07 | — | — | US | disclosed |
| US-9809565-B2 | Formation of chiral 4-chromanones using chiral pyrrolidines in the presence of ureas or thioureas | DSM IP ASSETS B.V. (NL) | 2017-11-07 | — | — | US | disclosed |
| EP-3016940-B1 | FORMATION OF CHIRAL 4-CHROMANONES USING CHIRAL PYRROLIDINES IN THE PRESENCE OF PHENOLS OR THIOPHENOLS | DSM IP ASSETS BV (NL) | 2017-04-12 | — | — | EP | disclosed |
| US-20160145228-A1 | FORMATION OF CHIRAL 4-CHROMANONES USING CHIRAL PYRROLIDINES IN THE PRESENCE OF UREAS OR THIOUREAS | DSM IP ASSETS B.V. (NL) | 2016-05-26 | — | — | US | disclosed |
| WO-2015001027-A1 | FORMATION OF CHIRAL 4-CHROMANONES USING CHIRAL PYRROLIDINES IN THE PRESENCE OF ACIDS | DSM IP ASSETS B.V. (NL) | 2015-01-08 | — | — | WO | disclosed |
| WO-2015001031-A1 | FORMATION OF CHIRAL 4-CHROMANONES USING CHIRAL PYRROLIDINES | DSM IP ASSETS B.V. (NL) | 2015-01-08 | — | — | WO | disclosed |
| WO-2015001030-A1 | FORMATION OF CHIRAL 4-CHROMANONES USING CHIRAL PYRROLIDINES IN THE PRESENCE OF UREAS OR THIOUREAS | DSM IP ASSETS B.V. (NL) | 2015-01-08 | — | — | WO | disclosed |
| WO-2015001029-A1 | FORMATION OF CHIRAL 4-CHROMANONES USING CHIRAL PYRROLIDINES IN THE PRESENCE OF PHENOLS OR THIOPHENOLS | DSM IP ASSETS B.V. (NL) | 2015-01-08 | — | — | WO | disclosed |
| US-8829208-B2 | Process for the preparation of darunavir and darunavir intermediates | MAPI PHARMA LTD. (IL) | 2014-09-09 | — | — | US | disclosed |
| US-20120296101-A1 | PROCESS FOR THE PREPARATION OF DARUNAVIR AND DARUNAVIR INTERMEDIATES | MAPI PHARMA LIMITED (IL) | 2012-11-22 | — | — | US | disclosed |
| US-20120296101-A1 | PROCESS FOR THE PREPARATION OF DARUNAVIR AND DARUNAVIR INTERMEDIATES | MAPI PHARMA LIMITED (IL) | 2012-11-22 | — | — | US | disclosed |
| EP-2366700-A1 | Pyrrolidine-thioxopyrimidinone/thiohydantoin organocatolysts | National and Kapodistrian Universty of Athens (GR) | 2011-09-21 | — | — | EP | disclosed |
| WO-2011092687-A1 | PROCESS FOR THE PREPARATION OF DARUNAVIR AND DARUNAVIR INTERMEDIATES | MAPI PHARMA HK LIMITED (CN) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230398529-A1 | ASYMMETRIC TRANSFER HYDROGENATION OF 2-ARYL SUBSTITUTED BICYCLIC PYRIDINE KETONES IN PRESENCE OF A CHIRAL RUTHENIUM CATALYST | ADH5, ADH1A, ADH1C | CYP3A4 166/4885CYP2D6 417/4885CYP1A2 86/4885 |
| US-20160145228-A1 | FORMATION OF CHIRAL 4-CHROMANONES USING CHIRAL PYRROLIDINES IN THE PRESENCE OF UREAS OR THIOUREAS | UCK2, UMPS, HCCS | CYP3A4 28/4885CYP2D6 391/4885CYP1A2 168/4885 |
| US-20120296101-A1 | PROCESS FOR THE PREPARATION OF DARUNAVIR AND DARUNAVIR INTERMEDIATES | CYP3A43, CYP3A4, DHPS | CYP3A4 2/4885CYP2D6 12/4885CYP1A2 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.